$ARTL
ARTELO BIOSCIENCES, INC. Stock $artl

$artl Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000164033420001749 Filed on July 13, 2020

Income Statement

Concept	2020 Q3	2020 Q2	2019 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$760.0K	$690.0K	$720.0K
YoY Change	5.56%	-9.21%	100.0%
% of Gross Profit
Research & Development	$270.0K	$265.2K	$230.0K
YoY Change	17.39%	43.97%	-30.3%
% of Gross Profit
Depreciation & Amortization	$0.00	$124.00	$0.00
YoY Change		-48.97%
% of Gross Profit
Operating Expenses	$1.030M	$951.4K	$950.0K
YoY Change	8.42%	1.07%	37.68%
Operating Profit		-$951.4K
YoY Change		1.07%
Interest Expense	$0.00	$0.00	$110.0K
YoY Change	-100.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	$204.00	$0.00
YoY Change		-99.97%
Pretax Income	-$1.030M	-$950.0K	-$850.0K
YoY Change	21.18%	179.41%	23.19%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.030M	-$951.2K	-$850.0K
YoY Change	21.18%	175.8%	23.19%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$224.9K	-$273.8K	-$283.3K
COMMON SHARES
Basic Shares Outstanding	4.496M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q3	2020 Q2	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.142M	$1.280M	$4.420M
YoY Change	-51.54%	341.38%	1200.0%
Cash & Equivalents	$2.142M	$1.279M	$4.424M
Short-Term Investments	$0.00
Other Short-Term Assets	$200.0K	$170.0K	$10.00K
YoY Change	1900.0%	-80.23%	-75.0%
Inventory
Prepaid Expenses	$195.0K	$74.66K	$18.62K
Receivables
Other Receivables
Total Short-Term Assets	$2.337M	$1.453M	$4.443M
YoY Change	-47.4%	26.32%	1010.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$246.00	$1.484K	$721.00
YoY Change	-65.88%
Goodwill
YoY Change
Intangibles	$2.039M	$2.039M	$2.039M
YoY Change	-0.02%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.039M	$2.041M	$2.040M
YoY Change	-0.06%
TOTAL ASSETS
Total Short-Term Assets	$2.337M	$1.453M	$4.443M
Total Long-Term Assets	$2.039M	$2.041M	$2.040M
Total Assets	$4.376M	$3.494M	$6.483M
YoY Change	-32.5%	203.78%	1520.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$490.0K	$260.0K	$639.4K
YoY Change	-23.37%	-71.43%	20.64%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$501.0K	$268.5K	$1.022M
YoY Change	-50.96%	-73.68%	92.74%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$501.0K	$268.5K	$1.022M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$501.0K	$270.0K	$1.020M
YoY Change	-50.88%	-73.53%	92.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$9.466M	-$8.438M	-$4.811M
YoY Change	96.77%
Common Stock	$5.000K	$3.734K	$3.354K
YoY Change	49.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.875M	$3.225M	$5.460M
YoY Change
Total Liabilities & Shareholders Equity	$4.376M	$3.494M	$6.483M
YoY Change	-32.5%	203.78%	1520.68%

Cashflow Statement

Concept	2020 Q3	2020 Q2	2019 Q3
OPERATING ACTIVITIES
Net Income	-$1.030M	-$951.2K	-$850.0K
YoY Change	21.18%	175.8%	23.19%
Depreciation, Depletion And Amortization	$0.00	$124.00	$0.00
YoY Change		-48.97%
Cash From Operating Activities	-$880.0K	-$1.020M	-$1.060M
YoY Change	-16.98%	72.88%	107.84%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$1.500M
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$1.500M
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.710M	280.0K	6.700M
YoY Change	-74.48%	-33.33%	1164.15%
NET CHANGE
Cash From Operating Activities	-880.0K	-1.020M	-1.060M
Cash From Investing Activities	0.000	0.000	-1.500M
Cash From Financing Activities	1.710M	280.0K	6.700M
Net Change In Cash	830.0K	-740.0K	4.140M
YoY Change	-79.95%	335.29%	20600.0%
FREE CASH FLOW
Cash From Operating Activities	-$880.0K	-$1.020M	-$1.060M
Capital Expenditures	$0.00	$0.00	-$1.500M
Free Cash Flow	-$880.0K	-$1.020M	$440.0K
YoY Change	-300.0%	72.88%	-186.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Amendment Flag AmendmentFlag	false
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	74655	USD
CY2019Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18623	USD
CY2020Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	98715	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1484	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	721	USD
CY2020Q2	us-gaap	Assets Assets	3493527	USD
CY2019Q3	us-gaap	Assets Assets	6482726	USD
CY2020Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	255632	USD
CY2019Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	348863	USD
CY2020Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	12825	USD
CY2019Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3732	USD
CY2019Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	29501	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	639417	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	3734	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	3354	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	50504	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9806	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	3708054	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	134379	USD
CY2019Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	32439	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1198	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	32439	USD
	artl	Change In Fair Value For Period Of Warrant Derivative Liability ChangeInFairValueForPeriodOfWarrantDerivativeLiability	897096	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-1370126	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-556903	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-424789	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9419	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3606	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.06
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3466385	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2058929	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3418148	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1898263	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0001621221
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	286439	USD
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	337424	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	1452626	USD
	dei	Trading Symbol TradingSymbol	ARTL
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1279256	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4423965	USD
	dei	Document Type DocumentType	10-Q
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4496366	shares
	dei	Document Period End Date DocumentPeriodEndDate	2020-05-31
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1144	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	792	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	268457	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1021513	USD
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	6250000	shares
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	6250000	shares
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	18750000	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Registrant Name EntityRegistrantName	ARTELO BIOSCIENCES, INC.
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019Q3	us-gaap	Assets Current AssetsCurrent	4442588	USD
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2039417	USD
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2039417	USD
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3733604	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	18750000	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3733604	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3353616	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3353616	shares
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	5461213	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	4963364	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6482726	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11609266	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10278421	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8438434	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4810756	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	3225070	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3493527	USD
CY2019Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	13000	USD
CY2019Q4	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	539417	USD
CY2019Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	100000	USD
CY2019Q4	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	155019	USD
	us-gaap	Professional Fees ProfessionalFees	785133	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	184204	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2616771	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	782351	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1646920	USD
CY2019Q2	us-gaap	Depreciation Depreciation	243	USD
	us-gaap	Depreciation Depreciation	372	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	941288	USD
	us-gaap	Operating Expenses OperatingExpenses	3658377	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-941288	USD
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2334937	shares
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2334937	shares
CY2019Q3	artl	Weighted Average Exercise Price WeightedAverageExercisePrice	8.12	USD
CY2020Q2	artl	Weighted Average Exercise Price WeightedAverageExercisePrice	8.12	USD
CY2019	artl	Warrants Weighted Average Life WarrantsWeightedAverageLife	P4Y3M21D
	artl	Warrants Weighted Average Life WarrantsWeightedAverageLife	P3Y6M18D
	artl	Number Of Warrant Granted NumberOfWarrantGranted	0	shares
	artl	Weighted Average Exercise Price Granted WeightedAverageExercisePriceGranted	0	USD
	artl	Number Of Warrant Forfeited NumberOfWarrantForfeited	0	shares
	artl	Weighted Average Exercise Price Forfeited WeightedAverageExercisePriceForfeited	0	USD
	artl	Number Of Warrant Exercised NumberOfWarrantExercised	0	shares
	artl	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	0	USD
CY2020Q2	artl	Warrant Intrinsic Value WarrantIntrinsicValue	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	74000	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	234000	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	281834	shares
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.88
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock entitles the holder to one vote, in person or proxy
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3658377	USD
CY2020Q2	artl	Change In Fair Value For Period Of Warrant Derivative Liability ChangeInFairValueForPeriodOfWarrantDerivativeLiability	0	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1225952	USD
CY2019Q2	us-gaap	Professional Fees ProfessionalFees	354038	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	402803	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	596405	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-344883	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3627678	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	-134974	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-475164	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-692174	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	382543	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	666226	USD
CY2020Q2	us-gaap	Professional Fees ProfessionalFees	303524	USD
	us-gaap	Professional Fees ProfessionalFees	731277	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	265204	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	858224	USD
CY2020Q2	us-gaap	Depreciation Depreciation	124	USD
	us-gaap	Depreciation Depreciation	383	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	951395	USD
	us-gaap	Operating Expenses OperatingExpenses	2256110	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-951395	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2256110	USD
CY2020Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	204	USD
CY2019Q2	artl	Change In Fair Value For Period Of Warrant Derivative Liability ChangeInFairValueForPeriodOfWarrantDerivativeLiability	563966	USD
	artl	Change In Fair Value For Period Of Warrant Derivative Liability ChangeInFairValueForPeriodOfWarrantDerivativeLiability	29501	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	204	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30699	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	929535	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-951191	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1326575	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-1306361	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y9M10D
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.57
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	26166	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.31
CY2019Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	771	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	60310	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	771	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	60310	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-344112	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3567368	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	376095	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-88231	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	91471	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3474667	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	34547	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2053	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	34547	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2053	USD
CY2019Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	16344	USD
CY2018Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4888	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-916644	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1324522	USD
CY2019Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	15151	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10500	USD
CY2018Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	13000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	13000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	100000	USD
CY2019Q4	artl	Adjustments To Additional Paid In Capital Refund For Fractional Stock AdjustmentsToAdditionalPaidInCapitalRefundForFractionalStock	-117	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	97397	USD
CY2020Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-2500	USD
CY2018Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	170774	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1087131	USD
CY2018Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	28051	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	29304	USD
CY2019Q1	artl	Reclass Of Warrant Derivative Liability From Equity ReclassOfWarrantDerivativeLiabilityFromEquity	-918050	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	326398	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	1176	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	7116	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	12222	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	270771	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1679772	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	60363	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	1511	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	artl	Common Shares Issued For Acquisition Of License Offset Against Stock Payable CommonSharesIssuedForAcquisitionOfLicenseOffsetAgainstStockPayable	539417	USD
	artl	Common Shares Issued For Settlement Of Stock Payable CommonSharesIssuedForSettlementOfStockPayable	100000	USD
	artl	Additional Issuance Series D Shares Per Terms Subscription Agreements AdditionalIssuanceSeriesDSharesPerTermsSubscriptionAgreements	7	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1176	USD
	artl	Refund For Fractional Stock RefundForFractionalStock	-117	USD
	artl	Cancellation Of Common Shares CancellationOfCommonShares	6	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.55	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.58	pure
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31500	USD
	artl	Remains Unamortized Allocated Share Based Compensation Expense RemainsUnamortizedAllocatedShareBasedCompensationExpense	44333	USD
	us-gaap	Nature Of Operations NatureOfOperations	<p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS</strong></span></span></span></span></p><p style="MARGIN:0px"> </p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">ARTELO BIOSCIENCES, INC. (“we”, “us”, “our”, the “Company”) is a Nevada corporation incorporated on May 2, 2011. It is based in San Diego County, California. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America, and the Company’s fiscal year end is August 31.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"> </p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Effective on February 10, 2017, the Company changed its name from “Knight Knox Development Corp.,” to “Reactive Medical Inc.” On April 14, 2017, the Company changed its name from “Reactive Medical Inc.” to “Artelo Biosciences, Inc.”</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"> </p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company registered fully owned subsidiaries in Ireland, Trinity Reliant Ventures Limited, on November 11, 2016 and in the UK, Trinity Research & Development Limited, on June 2, 2017. On January 8, 2020 Trinity Research and Development Limited changed its name to Artelo Biosciences Limited. The Company incorporated a fully owned subsidiary in Canada, Artelo Biosciences Corporation, on March 18, 2020. Operations in the subsidiaries have been consolidated in the financial statements.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"> </p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company intends to license, develop and commercialize novel cannabinoid therapeutic treatments.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"> </p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>Reverse stock split</em></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"> </p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company filed a Certificate of Change with the Secretary of State of Nevada, pursuant to which, effective on June 20, 2019, the Company effected a one-for-eight reverse split of its authorized and issued and outstanding common stock (the “Reverse Stock Split”). The number of authorized shares of common stock was reduced from 150,000,000 to 18,750,000. The Company’s authorized Preferred Stock was reduced from 50,000,000 to 6,250,000. All share and per share information in these financial statements retroactively reflect this reverse stock split.</span></span></p>
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.57
CY2020Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	139811	shares
CY2020Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	3.95
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M24D
	artl	Share Based Payment Stock Option Granted Weighted Average Remaining Life ShareBasedPaymentStockOptionGrantedWeightedAverageRemainingLife	P10Y
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	artl	Share Based Payment Stock Option Forfeited Weighted Average Remaining Life ShareBasedPaymentStockOptionForfeitedWeightedAverageRemainingLife	P9Y1M6D
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	15151	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10500	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	13000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	539417	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	42482	USD
CY2020Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-2500	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	380678	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	417732	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	39740	USD
CY2019Q2	artl	Reclass Of Warrant Derivative Liability From Equity ReclassOfWarrantDerivativeLiabilityFromEquity	-79224	USD
CY2019Q2	artl	Stock Issued During Period Value Issued For Services Related Party StockIssuedDuringPeriodValueIssuedForServicesRelatedParty	240000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	56027	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-24142	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1731580	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	688	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-688	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	380678	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1675637	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	113866	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-3040	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-8087	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3144709	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-50985	USD
	artl	Reclass Of Warrant Derivatives Liability From Equity ReclassOfWarrantDerivativesLiabilityFromEquity	997274	USD
	artl	Common Shares Issued For Deposit Of Acquisition Of License CommonSharesIssuedForDepositOfAcquisitionOfLicense	539417	USD
	artl	Deferred Offering Costs Incurred DeferredOfferingCostsIncurred	291670	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><em>Reclassification</em></strong></span></span></p><p style="MARGIN:0px;text-align:justify"> </p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Certain reclassifications have been made to the prior year financial statements to conform to the current period presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.</span></span></p></div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure

Files In Submission

Name	View Source	Status
0001640334-20-001749-index-headers.html	Edgar Link	pending
0001640334-20-001749-index.html	Edgar Link	pending
0001640334-20-001749.txt	Edgar Link	pending
0001640334-20-001749-xbrl.zip	Edgar Link	pending
artl-20200531.xml	Edgar Link	completed
artl-20200531.xsd	Edgar Link	pending
artl-20200531_cal.xml	Edgar Link	unprocessable
artl-20200531_def.xml	Edgar Link	unprocessable
artl-20200531_lab.xml	Edgar Link	unprocessable
artl-20200531_pre.xml	Edgar Link	unprocessable
artl_10q.htm	Edgar Link	pending
artl_ex311.htm	Edgar Link	pending
artl_ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTL
ARTELO BIOSCIENCES, INC. Stock $artl

2020 Q3 Form 10-Q Financial Statement

#000164033420001749 Filed on July 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTL ARTELO BIOSCIENCES, INC. Stock $artl

2020 Q3 Form 10-Q Financial Statement

#000164033420001749 Filed on July 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTL
ARTELO BIOSCIENCES, INC. Stock $artl